<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cent European J Urol</journal-id><journal-id journal-id-type="iso-abbrev">Cent European J Urol</journal-id><journal-id journal-id-type="publisher-id">CEJU</journal-id><journal-title-group><journal-title>Central European Journal of Urology</journal-title></journal-title-group><issn pub-type="ppub">2080-4806</issn><issn pub-type="epub">2080-4873</issn><publisher><publisher-name>Polish Urological Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24982780</article-id><article-id pub-id-type="pmc">4074719</article-id><article-id pub-id-type="publisher-id">00331</article-id><article-id pub-id-type="doi">10.5173/ceju.2014.01.art9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Effectiveness of combined high&#x02013;dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kosilov</surname><given-names>Kirill</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Loparev</surname><given-names>Sergey</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Iwanowskaya</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Kosilova</surname><given-names>Liliya</given-names></name><xref ref-type="aff" rid="AF0004">4</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Far Eastern Federal University, Vladivostok, Russia</aff><aff id="AF0002"><label>2</label>Department of Urology, City Hospital No. 3, Vladivostok, Russia</aff><aff id="AF0003"><label>3</label>Far Eastern National Fisheries University, Vladivostok, Russia</aff><aff id="AF0004"><label>4</label>Department of Functional Diagnostics Medical Association No. 2, Vladivostok, Russia</aff><author-notes><corresp id="cor1"><bold>Correspondence</bold> Kirill Kosilov, Ayax 10, Crp. S&#x02013;10B, Rvvo or 690069, Vladivostok, Russia. phone: +7 4232 89 147 173 915. <email xlink:href="oton2000@mail.ru">oton2000@mail.ru</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>4</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>67</volume><issue>1</issue><fpage>43</fpage><lpage>48</lpage><history><date date-type="received"><day>10</day><month>11</month><year>2013</year></date><date date-type="rev-recd"><day>19</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>15</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>Copyright by Polish Urological Association</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Material and methods</title><p>313 patients, 196 women and 117 men over 65 (average age 68.6) were included in this study. All patients underwent urodynamic examination before enrollment and after the study was completed. For clinical evaluation of LUT state ICIQ-SF questionnaires and bladder diaries were used. Patients with moderate (&#x00410;, n = 155) and severe (&#x00412;, n = 158) symptoms of OAB. Each group was divided into subgroups in which patients received Trospium 60 mg/day and Solifenacin 20 mg/day during two cycles &#x02013; 1.5 and 1 month with one month interval (&#x00410;1 and &#x00412;1); subgroups in which second cycle was substituted with placebo (&#x00410;2, &#x00412;2), and control groups (&#x00410;3, &#x00412;3).</p></sec><sec id="st2"><title>Results</title><p>In groups with moderate symptoms of OAB ratio of patients demonstrated decrease of frequency of EI &#x02265;1.5 a day remained at the level of 45-60% during all observation period. In subgroups with severe symptoms of OAB percentage of such patients was 55.3% for the subgroup which received two cycle therapy, and decreased to 26% in the subgroup which underwent 1 cycle therapy. Urodynamic indices for state of LUT correlated with clinical indicators (r =0.57-0.71 at p&#x02264; 0.05).</p></sec><sec id="st3"><title>Conclusions</title><p>Short single cycle of high-dosed Solifenacin and Trospium in elderly patients with moderate symptoms of OAB enables to maintain long therapeutic effect with acceptable level of side effects. This treatment algorithm applied in two cycle course is an effective and safe method for management of severe symptoms of OAB in elderly patients without increased risk of side effects.</p></sec></abstract><kwd-group><kwd>overactive bladder</kwd><kwd>elderly</kwd><kwd>antimuscarinic</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S0001"><title>INTRODUCTION</title><p>The prevalence of overactive bladder (OAB) symptoms in older age is very high, as evaluated by specialists [<xref rid="CIT0001" ref-type="bibr">1</xref>&#x02013;<xref rid="CIT0003" ref-type="bibr">3</xref>]. This high prevalence is associated with improved diagnostic methods, earlier detection of pathologies, general ageing of population, active raising of awareness among older adults about necessity to consult with specialist if symptoms of lower urinary tract disorders occur, and introduction of effective and safe drugs which can significantly improve quality of their lives [<xref rid="CIT0004" ref-type="bibr">4</xref>&#x02013;<xref rid="CIT0006" ref-type="bibr">6</xref>].</p><p>OAB symptoms include frequent urination, urgency, nocturia, and episodes of incontinence (EI). In spite of reports on successful use of antagonists of b3&#x02013;adrenoreceptors and other drugs [<xref rid="CIT0007" ref-type="bibr">7</xref>]; antimuscarinics, such as Trospium, Solifenacin, Darifenacin, remain drug of choice for management of OAB in elderly men and women. Clinical trials showed that these drugs significantly improve symptoms of OAB, including severe symptoms [<xref rid="CIT0008" ref-type="bibr">8</xref>&#x02013;<xref rid="CIT0010" ref-type="bibr">10</xref>]. The severity of OAB symptoms significantly varies amongst patients. To date, several studies have been performed in order to increase the effectiveness of management of OAB with varying severity using different doses of well&#x02013;known antimuscarinics [<xref rid="CIT0011" ref-type="bibr">11</xref>, <xref rid="CIT0012" ref-type="bibr">12</xref>]. Nevertheless, the issue concerning reactions of patients with various symptoms of OAB to different treatment algorithms requires further research. Its solution will avoid excessive drug administration when possible, and ultimately result in a decreased risk of adverse effects.</p><p>The frequency of EI per day or per week is used, among other indicators, for the evaluation of clinical effectiveness of management of OAB symptoms [<xref rid="CIT0012" ref-type="bibr">12</xref>]. Importance of this indicator of the state of the lower urinary tract (LUT) is confirmed by its high level of correlation with subjective patient&#x02013;reported outcomes, such as the Patient's Perception of Bladder Condition (PPBC), health related quality of life (HRQoL), parameters of urodynamic state, and other clinical symptoms. In several studies, a value of EI &#x0003e;21/week or EI &#x0003e;3/day is used for determining severity of OAB symptoms based on comparison of this parameter with other clinical and urodynamic indices [<xref rid="CIT0013" ref-type="bibr">13</xref>, <xref rid="CIT0014" ref-type="bibr">14</xref>]. In our work we were guided by these data and considered them proven and persuasive.</p><p>In the previous study we demonstrated the effectiveness and safety of management of OAB in elderly men and women with combined high&#x02013;dose antimuscarinics [<xref rid="CIT0015" ref-type="bibr">15</xref>]. This study follows the previous one; its aim is to determine an optimal algorithm of drug management of OAB in elderly men and women with varying severities of symptoms and to assess the necessity of cyclic treatment according to the proposed algorithm in order to maintain a long term positive therapeutic effect.</p></sec><sec sec-type="materials|methods" id="S0002"><title>MATERIAL AND METHODS</title><p>The study was performed from June 1, 2010 to June 30, 2012 using principles of randomization, blind random assignment method, and placebo control.</p><p>313 patients, 196 women and 117 men over 65 (average age 68.6) were included in this study (<xref ref-type="table" rid="T0001">Table 1</xref>). In accordance with research protocol, the main criteria for exclusion included intolerance of antimuscarinic drugs, any pathological conditions in which antimuscarinics are contraindicated, and presence of organic damage of the central nervous system. Patients were distributed into groups and research was performed in accordance with Good Clinical Practice (GCP) and the Declaration of Helsinki.[<xref rid="CIT0016" ref-type="bibr">16</xref>, <xref rid="CIT0017" ref-type="bibr">17</xref>] All patients in the groups demonstrated clinically and urodynamically proven OAB dysfunction. Clinical profiles of patients are shown in tables No. 1, 2.
</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Baseline Characteristics of patients (n = 313; 298)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="center" colspan="2" rowspan="1">Group taking solifenacin 60 mg + trospium 40 mg &#x02013; 2 cycles</th><th align="center" colspan="2" rowspan="1">Group taking solifenacin 60 mg + trospium 40 mg &#x02013; 1 cycle and placebo &#x02013; 1 cycle</th><th align="center" colspan="2" rowspan="1">Group taking placebo</th></tr><tr><th colspan="7" rowspan="1">
<hr/>
</th></tr><tr><th align="left" rowspan="1" colspan="1">Severity of Symptoms of OAB</th><th align="center" rowspan="1" colspan="1">Moderate<xref ref-type="table-fn" rid="TF0001">*</xref> Group A1</th><th align="center" rowspan="1" colspan="1">Severe<xref ref-type="table-fn" rid="TF0002">**</xref> Group A2</th><th align="center" rowspan="1" colspan="1">Moderate Group B1</th><th align="center" rowspan="1" colspan="1">Severe Group B2</th><th align="center" rowspan="1" colspan="1">Moderate Group A3</th><th align="center" rowspan="1" colspan="1">Severe Group B3</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of patients</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">57</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean age in years</td><td align="center" rowspan="1" colspan="1">69.8 (7.8)</td><td align="center" rowspan="1" colspan="1">67.0 (11.4)</td><td align="center" rowspan="1" colspan="1">71.3 (6.9)</td><td align="center" rowspan="1" colspan="1">69.1 (5.9)</td><td align="center" rowspan="1" colspan="1">69.7 (7.9)</td><td align="center" rowspan="1" colspan="1">67.8 (13.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median incontinence episodes/day, n</td><td align="center" rowspan="1" colspan="1">2.6 (0.9)</td><td align="center" rowspan="1" colspan="1">4.7 (0.4)</td><td align="center" rowspan="1" colspan="1">2.8 (0.6)</td><td align="center" rowspan="1" colspan="1">5.4 (1.2)</td><td align="center" rowspan="1" colspan="1">2.8 (0.4)</td><td align="center" rowspan="1" colspan="1">5.3 (0.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median urgency episodes/day, n</td><td align="center" rowspan="1" colspan="1">3.0 (1.1)</td><td align="center" rowspan="1" colspan="1">5.1 (1.3)</td><td align="center" rowspan="1" colspan="1">3.5 (0.5)</td><td align="center" rowspan="1" colspan="1">5.5 (0.9)</td><td align="center" rowspan="1" colspan="1">3.4 (1.2)</td><td align="center" rowspan="1" colspan="1">6.1 (0.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median number of urination/day, n</td><td align="center" rowspan="1" colspan="1">8.9 (1.9)</td><td align="center" rowspan="1" colspan="1">11.7 (1.9)</td><td align="center" rowspan="1" colspan="1">9.7 (2.6)</td><td align="center" rowspan="1" colspan="1">12.4 (4.1)</td><td align="center" rowspan="1" colspan="1">9.1 (1.1)</td><td align="center" rowspan="1" colspan="1">12.3 (2.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median volume voided/once, ml</td><td align="center" rowspan="1" colspan="1">145.8 (13.5)</td><td align="center" rowspan="1" colspan="1">129.8 (17.9)</td><td align="center" rowspan="1" colspan="1">157.8 (9.0)</td><td align="center" rowspan="1" colspan="1">107.8 (17.6)</td><td align="center" rowspan="1" colspan="1">155.8 (21.9)</td><td align="center" rowspan="1" colspan="1">125.9 (13.3)</td></tr></tbody></table><table-wrap-foot><fn id="TF0001"><label>*</label><p>Patients with moderate OAB baseline symptoms (&#x02264;3 incontinence episodes per day)</p></fn><fn id="TF0002"><label>**</label><p>Patients with severe OAB baseline symptoms (&#x02265;3 incontinence episodes per day)</p></fn></table-wrap-foot></table-wrap><p>All patients underwent urodynamic examination before enrollment and after the study was completed (in 6 months) results of reflex volume, bladder capacity, detrusor compliance, and post&#x02013;void residual volume were recorded. The urodynamic state of the lower urinary tract was evaluated using the &#x0201c;Relief&#x02013;01&#x0201d; (DALPRIBOR, Vladivostok, Russia) system with a double catheter microtip (Apexmed International B.V., Netherlands) [<xref rid="CIT0018" ref-type="bibr">18</xref>, <xref rid="CIT0019" ref-type="bibr">19</xref>].</p><p>For the clinical evaluation of urinary dysfunction we used an ICIQ&#x02013;SF questionnaire recommended by ICS and bladder diaries in which frequency of urinations, incontinence events per day, amount of urine while urinating, and number of urgencies were recorded. Additionally, patients were asked to note any signs of unwellness in their diaries (without limited lists of side effects) [<xref rid="CIT0020" ref-type="bibr">20</xref>&#x02013;<xref rid="CIT0022" ref-type="bibr">22</xref>].</p><p>The frequency of incontinency events was used as a measure of severity. In case of EI &#x02264;3 per day, severity of symptoms was considered to be moderate, in case of EI &#x02265;3 per day severity of symptoms was considered to be significant [<xref rid="CIT0012" ref-type="bibr">12</xref>]. In accordance with severity criteria, patients were distributed into two main groups: patients with moderate (&#x00410;, n = 155) and severe (&#x00412;, n = 158) symptoms of OAB. The groups were then further divided into subgroups depending on their treatment algorithm. Patients from groups &#x00410;<sup>1</sup>and &#x00412;<sup>1</sup> (n = 50; 54) received Trospium 60 mg/day and Solifenacin 20 mg/day for 6 weeks and again for 4 weeks following a 6 week&#x02013;interval; for a total of 2 cycles. Patients from subgroups &#x00410;<sup>2</sup> and &#x00412;<sup>2</sup> (n = 47; 47) received the same treatment as the previous groups during the first cycle and during the second cycle &#x02013; placebo. Patients in subgroups &#x00410;<sup>3</sup> and &#x00412;<sup>3</sup> (n = 58; 57) received placebo during both cycles (<xref ref-type="fig" rid="F0001">Figure 1</xref>).</p><fig id="F0001" position="float"><label>Figure 1</label><caption><p>Algorithm of examination and treatment of elderly patients with varying baseline symptom severity.</p></caption><graphic xlink:href="CEJU-67-00331-g001"/></fig><p>Initial data was collected using the Excel program of standard package Microsoft&#x02013;&#x00425;&#x00420; (Microsoft&#x02013;Rus, Vladivostok, Russia) and analyzed with the statistical analysis program SAS JMP Statistical Discovery 8.0.2 (SAS Institute, Cary, NC, USA). The Wilcoxon test was used to compare results in each treatment group before and after examination; the Kruskal&#x02013;Wallis rank test was used for control of equality of medians from different groups. One&#x02013;way analysis of variance (ANOVAs) with Tukey&#x02013;Kramer honestly significant difference was used to compare effects in the three groups. Standard deviation P values of &#x0003c; 0.05 were considered statistically significant.</p></sec><sec sec-type="results" id="S0003"><title>RESULTS</title><p>Improvement of incontinence events in patients with moderate symptoms in the course of treatment is shown in <xref ref-type="fig" rid="F0002">Figure 2A</xref>. Steady decrease of incontinence events in subgroups &#x00410;<sup>1</sup> and &#x00410;<sup>2</sup>, both in subgroups which underwent two&#x02013;cycle therapy and in the subgroup with one cycle treatment, was observed. Improvement continued for up to 6 months; a significant difference between subgroups was not found (&#x02013;2.2; &#x02013;1.8 p &#x02265;0.05). In the group of patients who received placebo, improvement of the indicator was insignificant. In the groups of patients with severe symptoms of OAB (<xref ref-type="fig" rid="F0002">Figure 2B</xref>) improvements of the indicator differed as follows: decrease of EI was steady only for the group in which patients underwent two cycle therapy (&#x00412;<sup>1</sup>); in group &#x00412;<sup>2</sup> improvements significantly slowed by 4<sup>th</sup> month and by 6<sup>th</sup> month it was statistically equivalent to the group in which patients received placebo (&#x00412;<sup>1</sup> = &#x02013;3.1(0.4); &#x00412;<sup>2</sup> = &#x02013;0.9 (0.2); p &#x02264;0.05).</p><fig id="F0002" position="float"><label>Figure 2</label><caption><p>Impact of solifenacin and trospium on urinary incontinence episodes per day over time in patients with OAB according to baseline symptom severity.</p></caption><graphic xlink:href="CEJU-67-00331-g002"/></fig><p>Changes in urinary urgency for patients with moderate symptoms (<xref ref-type="fig" rid="F0003">Figure 3&#x00410;</xref>) also did not depend on number of cycles of the therapy. In subgroups &#x00410;<sup>1</sup>and &#x00410;<sup>2</sup> decrease was steady until completion of the therapy [&#x02013;2.7 (1.0); &#x02013;2.3 (0.8); p &#x02265;0.05]; in placebo group (&#x00410;<sup>3</sup>) it remained at the minimal level during all period of records. In subgroups with severe symptoms of OAB results were different. In subgroup &#x00412;<sup>1</sup> values of the indicator changed insignificantly, in subgroup &#x00412;<sup>2</sup> urinary urgency increased dramatically by the 5<sup>th</sup> month of observation [(&#x02013;0.9 (0.7)]. In subgroup &#x00412;<sup>3</sup> values remained within statistical error.</p><fig id="F0003" position="float"><label>Figure 3</label><caption><p>Effectiveness of solifenacin and trospium on urinary urgency episodes per day over time in patients with OAB according to baseline symptom severity.</p></caption><graphic xlink:href="CEJU-67-00331-g003"/></fig><p>The analysis of number of patients, who demonstrated decrease of incontinence events to &#x02265;1.5 per day, allowed us to find the following regularity (<xref ref-type="fig" rid="F0004">Figure 4&#x00410;,B</xref>). In groups with moderate severity of OAB symptoms, the ratio of such patients remained at the level of 45&#x02013;60% during the entire observation period. In subgroup &#x00412;<sup>1</sup> (two cycle therapy), the percentage of patients who demonstrated significant decrease of EI was 55.3% at the 6<sup>th</sup> month and did not change significantly during the examination period. In the subgroup with one&#x02013;cycle therapy, by the end of examination the amount of such patients did not exceed 26%.</p><fig id="F0004" position="float"><label>Figure 4</label><caption><p>Ratio of patient overtime a reduction over 1.5 incontinence episodes per day according to baseline symptom severity.</p></caption><graphic xlink:href="CEJU-67-00331-g004"/></fig><p>Analysis of urodynamic data before and after therapy made it possible to confirm tendencies of the dynamics of various clinical symptoms. In groups with moderate OAB symptoms (&#x00410;<sup>1</sup>, &#x00410;<sup>2</sup>) parameters such as reflex volume, bladder capacity, and detrusor compliance were significantly high in comparison with starting levels (<xref ref-type="table" rid="T0002">Table 2</xref>). Increase of level of post&#x02013;void residual volume was insignificant. In groups with severe symptoms, parameters were different: in subgroup &#x00412;<sup>2</sup> only volume index demonstrated significant difference; on the contrary, in subgroup &#x00412;<sup>1</sup> all urodynamic indices were different from initial with p&#x02264;0.001.
</p><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Result of urodynamic (n = 313; 298)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Form of control</th><th align="center" colspan="8" rowspan="1">Indicators of urodynamics (&#x000b1;SD)</th></tr><tr><th colspan="9" rowspan="1">
<hr/>
</th></tr><tr><th align="left" rowspan="1" colspan="1">Parameters of the LUT</th><th align="center" colspan="2" rowspan="1">Post&#x02013;void residual (ml)</th><th align="center" colspan="2" rowspan="1">Reflex volume (ml)</th><th align="center" colspan="2" rowspan="1">Bladder capacity (ml)</th><th align="center" colspan="2" rowspan="1">Detrusor compliance (ml/cm H<sub>2</sub>O)</th></tr><tr><th colspan="9" rowspan="1">
<hr/>
</th></tr><tr><th align="left" rowspan="1" colspan="1">Ttime of study</th><th align="center" rowspan="1" colspan="1">Before treat</th><th align="center" rowspan="1" colspan="1">After treat</th><th align="center" rowspan="1" colspan="1">Before treat</th><th align="center" rowspan="1" colspan="1">After treat</th><th align="center" rowspan="1" colspan="1">Before treat</th><th align="center" rowspan="1" colspan="1">After treat</th><th align="center" rowspan="1" colspan="1">Before treat</th><th align="center" rowspan="1" colspan="1">After treat</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Group A1 (n = 50)</td><td align="center" rowspan="1" colspan="1">18.7 (7.4)</td><td align="center" rowspan="1" colspan="1">34.1 (5.7) <xref ref-type="table-fn" rid="TF0004">*</xref></td><td align="center" rowspan="1" colspan="1">164.6 (26.3)</td><td align="center" rowspan="1" colspan="1">275.3 (45.3)<xref ref-type="table-fn" rid="TF0005">**</xref></td><td align="center" rowspan="1" colspan="1">217.6 (24.6)</td><td align="center" rowspan="1" colspan="1">317.7 (35.6)<xref ref-type="table-fn" rid="TF0005">**</xref></td><td align="center" rowspan="1" colspan="1">24.3 (3.3)</td><td align="center" rowspan="1" colspan="1">36.3 (5.4)<xref ref-type="table-fn" rid="TF0004">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Group A2 (n = 47)</td><td align="center" rowspan="1" colspan="1">15.8 (12.2)</td><td align="center" rowspan="1" colspan="1">23.7 (4.9)</td><td align="center" rowspan="1" colspan="1">173.5 (41.5)</td><td align="center" rowspan="1" colspan="1">212.3 (35.9)</td><td align="center" rowspan="1" colspan="1">201.3 (37.7)</td><td align="center" rowspan="1" colspan="1">247.9 (26.8)</td><td align="center" rowspan="1" colspan="1">20.8 (1.5)</td><td align="center" rowspan="1" colspan="1">25.6 (2.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Group A3 (n = 58)</td><td align="center" rowspan="1" colspan="1">22.3 (4.8)</td><td align="center" rowspan="1" colspan="1">21.9 (9.2)</td><td align="center" rowspan="1" colspan="1">148.2 (37.8)</td><td align="center" rowspan="1" colspan="1">153.6 (44.2)</td><td align="center" rowspan="1" colspan="1">188.4 (47.4)</td><td align="center" rowspan="1" colspan="1">211.7 (34.3)</td><td align="center" rowspan="1" colspan="1">23.9 (11.6)</td><td align="center" rowspan="1" colspan="1">25.7 (4.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Group B1 (n = 54)</td><td align="center" rowspan="1" colspan="1">18.5 (4.7)</td><td align="center" rowspan="1" colspan="1">31.7 (5.8)<xref ref-type="table-fn" rid="TF0004">*</xref></td><td align="center" rowspan="1" colspan="1">121.4 (30.5)</td><td align="center" rowspan="1" colspan="1">285.7 (64.2)<xref ref-type="table-fn" rid="TF0005">**</xref></td><td align="center" rowspan="1" colspan="1">155.6 (47.8)</td><td align="center" rowspan="1" colspan="1">277.4 (35.6)<xref ref-type="table-fn" rid="TF0005">**</xref></td><td align="center" rowspan="1" colspan="1">15.8 (2.5)</td><td align="center" rowspan="1" colspan="1">33.5 (6.3)<xref ref-type="table-fn" rid="TF0005">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Group B2 (n = 47)</td><td align="center" rowspan="1" colspan="1">21.2 (4.6)</td><td align="center" rowspan="1" colspan="1">29.2 (9.4)</td><td align="center" rowspan="1" colspan="1">141.2 (15.8)</td><td align="center" rowspan="1" colspan="1">186.2 (14.5)<xref ref-type="table-fn" rid="TF0004">*</xref></td><td align="center" rowspan="1" colspan="1">178.4 (47.4)</td><td align="center" rowspan="1" colspan="1">201.7 (34.3)</td><td align="center" rowspan="1" colspan="1">17.7 (4.4)</td><td align="center" rowspan="1" colspan="1">23.5 (4.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Group B3 (n = 57)</td><td align="center" rowspan="1" colspan="1">22.6 (6.6)</td><td align="center" rowspan="1" colspan="1">19.1 (6.2)</td><td align="center" rowspan="1" colspan="1">136.6 (32.5)</td><td align="center" rowspan="1" colspan="1">115.6 (36.3)</td><td align="center" rowspan="1" colspan="1">159.5 (34.6)</td><td align="center" rowspan="1" colspan="1">145.4 (44.3)</td><td align="center" rowspan="1" colspan="1">17.3 (2.3)</td><td align="center" rowspan="1" colspan="1">16.4 (4.6)</td></tr></tbody></table><table-wrap-foot><fn><p>SD &#x02013; standard deviation</p></fn><fn id="TF0004"><label>*</label><p>&#x0003c; 0.05</p></fn><fn id="TF0005"><label>**</label><p>&#x0003c; 0.001</p></fn><fn><p>&#x0201c;Before treat&#x0201d;&#x02013; amounts taken at onset of study and considered baseline, &#x0201c;After treat&#x0201d;&#x02013; 6 months from the start of the study</p></fn></table-wrap-foot></table-wrap><p>During the period of the study, 15 (4.8%) people stopped their treatment. Among them 9 patients stopped due to development of side effects (6 &#x02013; dry mouth, 1&#x02013; headaches, 1 &#x02013; rash and itching, 1 &#x02013; diarrhea). Three patients stopped their treatment because they did not experience any satisfactory results (at 2<sup>nd</sup>, 4<sup>th</sup> and 5<sup>th</sup> weeks of first cycle). In 2 cases treatment was discontinued due to circumstances not related to the treatment. One patient died of acute heart failure (not in the period of administration of the drugs).</p><p>37 (11.8%) patients reported side effects, but their severity was moderate, therefore it was not the reason for stopping treatment. In 19 cases this symptom was dry mouth, in 5 &#x02013; rash and skin itching, in 6 &#x02013; nausea, in 4 &#x02013; diarrhea, in 2 &#x02013; headache, and in 1 &#x02013; transient colour vision disorder. One patient suffered acute urinary retention, which disappeared during one day.</p></sec><sec sec-type="discussion" id="S0004"><title>DISCUSSION</title><p>It is well known that approximately 30% of patients do not benefit from antimuscarinics administered at standard dosage [<xref rid="CIT0023" ref-type="bibr">23</xref>&#x02013;<xref rid="CIT0025" ref-type="bibr">25</xref>]. In previous studies it was concluded that an increase of doses of antimuscarinic drugs of 1.5&#x02013;2 times is well tolerated; without a rise, in most cases, of the quantity and strength of side effects [<xref rid="CIT0026" ref-type="bibr">26</xref>, <xref rid="CIT0027" ref-type="bibr">27</xref>].</p><p>In our previous study we concluded that combination of high&#x02013;dosed Trospium and Solifenacin in elderly patients enables the decrease of OAB symptoms significantly with an acceptable level of side effects and absence of complications [<xref rid="CIT0015" ref-type="bibr">15</xref>].</p><p>In this study we tried to determine effectiveness of one and two cycle therapy, with these high&#x02013;dosed antimuscarinics, in elderly patients with different severity of OAB symptoms. It was established that a one&#x02013;cycle, 1.5&#x02013;month long treatment in elderly patients with moderate OAB resulted in significantly different symptom parameters of OAB from that of initial levels at the beginning of the study to those at the 6<sup>th</sup> month after treatment. In patients with severe symptoms of OAB, the total level of markers returns to the initial level by the 4th&#x02013;5th month of observation. At two&#x02013;cycle treatment, independent of severity of initial symptoms, parameters of state of LUT are significantly different from the initial parameters.</p><p>In other words, two&#x02013;cycle treatment in accordance with proposed regimen provides satisfactory therapeutic effect under any severity of OAB; one&#x02013;cycle treatment is sufficient for maintaining therapeutic effect for at least 6 months only in patients with moderate symptoms.</p><p>It is well known that the M<sub>2</sub>&#x02013;muscarinic receptors are the predominant receptors in the urinary bladder. M<sub>3</sub>&#x02013;muscarinic receptors are more efficient but they are represented in a lower amount. Relatively recently, pre&#x02013;junctional&#x02013;inhibitory M<sub>2</sub>&#x02013; or M<sub>4</sub>&#x02013;muscarinic receptors and M<sub>1</sub>&#x02013;muscarinic receptors were detected in the urinary bladder. There are articles stating that the &#x0041c;<sub>2</sub>&#x02013;muscarinic receptors in urinary bladder of elderly people are the first to undergo involution. From this point of view, Solifenacin, which is a specific competitive inhibitor of mainly &#x0041c;<sub>3</sub>&#x02013;subtype of receptors, and Trospium, which has high affinity to all muscarinic receptors, are chosen for management of OAB in elderly men and women. Elderly patients tolerate high doses of these drugs comparatively well and effectiveness of such combinations is high [<xref rid="CIT0028" ref-type="bibr">28</xref>&#x02013;<xref rid="CIT0033" ref-type="bibr">33</xref>].</p><p>It can be assumed that the high stability of therapeutic effect in patients with moderate symptoms of OAB is ensured by some cumulative effect at influencing &#x0201c;elderly bladder&#x0201d; &#x0041c;<sub>3</sub> receptors, which remained in satisfactory condition, as well as by the synergistic effect of two antimuscarinics with different spectrums. Probably such a reaction of the urinary bladder is also caused by the influence of drugs on specific receptors of urothelial and myogenic afferent pathways and suppression of &#x0201c;afferent noise&#x0201d; at this level [<xref rid="CIT0032" ref-type="bibr">32</xref>]. In this case, a second cycle of antimuscarinics strengthens suppression of excessive action of receptors and obtains a significant effect for a comparatively longer period of time in patients with severe symptoms of OAB. Obtained results make it possible to receive satisfactory therapeutic effect in patients with moderate symptoms under a short therapeutic course lasting less than 6 months. We believe that this has important applied meaning given the fact that elderly patients follow prescriptions quite poorly and quickly get tired of long therapeutic courses.</p><p>We suppose that further study of bladder reaction, especially in elderly patients with moderate symptoms of OAB, to various doses of combined antimuscarinics, is necessary in order to decrease drug load.</p></sec><sec sec-type="conclusion" id="S0005"><title>CONCLUSIONS</title><p>Short cycle of high&#x02013;dosed Solifenacin and Trospium in elderly patients with moderate symptoms of OAB enables to maintain long therapeutic effect with acceptable level of side effects. It has important applied meaning for elderly men and women who are not good at exactly following prescriptions for a long time.</p><p>Combinations of high&#x02013;dosed Solifenacin and Trospium in two&#x02013;cycle treatment is an effective and safe method for management of severe symptoms of OAB in elderly patients without increased risk of side effects.</p></sec></body><back><ref-list><title>References</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milsom</surname><given-names>I</given-names></name><name><surname>Coyne</surname><given-names>KS</given-names></name><name><surname>Nicholson</surname><given-names>S</given-names></name><name><surname>Kvasz</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>CI</given-names></name><name><surname>Wein</surname><given-names>AJ</given-names></name></person-group><article-title>Global Prevalence and Economic Burden of Urgency Urinary Incontinence: A Systematic Review</article-title><source>Eur Urol.</source><year>2013</year><volume>65</volume><fpage>79</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">24007713</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruffion</surname><given-names>A</given-names></name><name><surname>Castro&#x02013;Diaz</surname><given-names>D</given-names></name><name><surname>Patel</surname><given-names>H</given-names></name><name><surname>Khalaf</surname><given-names>K</given-names></name><name><surname>Onyenwenyi</surname><given-names>A</given-names></name><name><surname>Globe</surname><given-names>D</given-names></name><etal/></person-group><article-title>Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder</article-title><source>Neuroepidemiology.</source><year>2013</year><volume>41</volume><fpage>146</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">23942583</pub-id></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milsom</surname><given-names>I</given-names></name><name><surname>Stewart</surname><given-names>W</given-names></name><name><surname>Thuroff</surname><given-names>J</given-names></name></person-group><article-title>The prevalence of overactive bladder</article-title><source>Am J Manag Care</source><year>2000</year><volume>6</volume><issue>Suppl</issue><fpage>S565</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">11183899</pub-id></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heesakkers</surname><given-names>JP</given-names></name><name><surname>Cruz</surname><given-names>F</given-names></name><name><surname>Igawa</surname><given-names>Y</given-names></name><name><surname>Kocjancic</surname><given-names>E</given-names></name></person-group><article-title>Overactive bladder: pathophysiology, diagnostics, and therapies</article-title><source>Adv Urol.</source><year>2011</year><volume>2011</volume><fpage>863504</fpage><pub-id pub-id-type="pmid">22761613</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rantell</surname><given-names>A</given-names></name></person-group><article-title>Assessment and diagnosis of overactive bladder in women</article-title><source>Nurs Stand.</source><year>2013</year><volume>27</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">23980988</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griebling</surname><given-names>TL</given-names></name></person-group><article-title>Overactive bladder in elderly men: epidemiology, evaluation, clinical effects, and management</article-title><source>Curr Urol Rep.</source><year>2013</year><volume>14</volume><fpage>418</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">23913201</pub-id></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>K.&#x02013;E</given-names></name></person-group><article-title>New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA</article-title><source>Ther Clin Risk Manag.</source><year>2013</year><volume>9</volume><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">23637536</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natalin</surname><given-names>R</given-names></name><name><surname>Lorenzetti</surname><given-names>F</given-names></name><name><surname>Dambros</surname><given-names>M</given-names></name></person-group><article-title>Management of OAB in Those Over Age 65</article-title><source>Curr Urol Rep.</source><year>2013</year><volume>14</volume><fpage>379</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">23922134</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagg</surname><given-names>AS</given-names></name><name><surname>Cardozo</surname><given-names>L</given-names></name><name><surname>Chapple</surname><given-names>Ch</given-names></name><name><surname>De Ridder</surname><given-names>D</given-names></name><name><surname>Kelleher</surname><given-names>C</given-names></name><name><surname>Kirby</surname><given-names>M</given-names></name><etal/></person-group><article-title>Overactive bladder syndrome in older people</article-title><source>BJU Int.</source><year>2007</year><volume>99</volume><fpage>3</fpage><pub-id pub-id-type="pmid">17227485</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Miyamae</surname><given-names>K</given-names></name><name><surname>Iwashita</surname><given-names>H</given-names></name><name><surname>Otani</surname><given-names>M</given-names></name><name><surname>Inadome</surname><given-names>A</given-names></name></person-group><article-title>Management detrusor dysfunction in the elderly: changes in acetylcholine and adenos triphosphate release during aging</article-title><source>Urology</source><year>2004</year><volume>63</volume><issue>Suppl 1</issue><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">15013648</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JM</given-names></name><name><surname>Fulton</surname><given-names>RG</given-names></name><name><surname>Amundsen</surname><given-names>CL</given-names></name><name><surname>Knight</surname><given-names>SK</given-names></name><name><surname>Kuppermann</surname><given-names>M</given-names></name></person-group><article-title>Patient preferences for different severities of and treatments for overactive bladder</article-title><source>Female Pelvic Med Reconstr Surg.</source><year>2011</year><volume>174</volume><fpage>184</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">22453849</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dmochowski</surname><given-names>RR</given-names></name><name><surname>Larson&#x02013;Peters</surname><given-names>A</given-names></name><name><surname>Aronstein</surname><given-names>WS</given-names></name><name><surname>Seifu</surname><given-names>Y</given-names></name></person-group><article-title>Efficacy of Darifenacin in Patients with Varying Baseline Symptom Severity</article-title><source>UIJ</source><year>2009</year></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diokno</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Zorn</surname><given-names>BH</given-names></name><name><surname>Lenderking</surname><given-names>WR</given-names></name><name><surname>Grossman</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Factors associated with clinical assessment of overactive bladder and selection of treatment</article-title><source>Clin Ther.</source><year>2001</year><volume>23</volume><fpage>1542</fpage><lpage>1551</lpage><pub-id pub-id-type="pmid">11589266</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coyne</surname><given-names>KS</given-names></name><name><surname>Matza</surname><given-names>LS</given-names></name><name><surname>Kopp</surname><given-names>Z</given-names></name><name><surname>Abrams</surname><given-names>P</given-names></name></person-group><article-title>The validation of the patient perception of bladder condition (PPBC): a single&#x02013;item global measure for patients with overactive bladder</article-title><source>Eur Urol.</source><year>2006</year><volume>49</volume><fpage>1079</fpage><lpage>1086</lpage><pub-id pub-id-type="pmid">16460875</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosilov</surname><given-names>K</given-names></name><name><surname>Loparev</surname><given-names>S</given-names></name><name><surname>Ivanovskaya</surname><given-names>M</given-names></name><name><surname>Kosilova</surname><given-names>L</given-names></name></person-group><article-title>Management of Overactive Bladder (OAB) in Elderly Men and Women with Combined, High&#x02013;Dosed Antimuscarinics without Increased Side Effects</article-title><source>UroToday Int J</source><year>2013</year><volume>6</volume><comment>art 47</comment></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroder</surname><given-names>A</given-names></name><name><surname>Abrams</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>K.&#x02013;E</given-names></name><name><surname>Artibani</surname><given-names>W</given-names></name><name><surname>Chapple</surname><given-names>C.R</given-names></name><name><surname>Drake</surname><given-names>M.J</given-names></name></person-group><article-title>Guidelines on Urinary Incontinence European Association of Urology</article-title><year>2009</year><fpage>S 52</fpage></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdem</surname><given-names>N</given-names></name><name><surname>Chu</surname><given-names>F</given-names></name></person-group><article-title>Management of overactive bladder disease and urge urinary incontinence in the elderly patient</article-title><source>Am J Med.</source><year>2006</year><volume>119</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16483866</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurpreet</surname><given-names>Singh</given-names></name><name><surname>Malcolm</surname><given-names>Lucas</given-names></name><name><surname>Lucia</surname><given-names>Dolan</given-names></name><name><surname>Stephanie</surname><given-names>Knight</given-names></name><name><surname>Carmel</surname><given-names>Ramage</given-names></name><name><surname>Philip</surname><given-names>Toozs Hobson</given-names></name></person-group><article-title>Minimum standards for urodynamic practice in the UK</article-title><source>Neurol Urodyn</source><year>2010</year><volume>29</volume><fpage>1365</fpage><lpage>1372</lpage></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>W</given-names></name><name><surname>Abrams</surname><given-names>P</given-names></name><name><surname>Liao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Good urodynamic practices: uroflowmetry, filling cystometry, and pressure&#x02013;flow studies</article-title><source>Neurol. Urodyn.</source><year>2002</year><volume>21</volume><fpage>261</fpage><lpage>274</lpage></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>M</given-names></name><name><surname>Amundsen</surname><given-names>CL</given-names></name><name><surname>Cardozo</surname><given-names>L</given-names></name><name><surname>Vella</surname><given-names>M</given-names></name><name><surname>Webster</surname><given-names>GD</given-names></name><name><surname>Coats</surname><given-names>AC</given-names></name></person-group><article-title>Bladder diary patterns in detrusor overactivity and urodynamic stress incontinence</article-title><source>Neurourol Urodyn.</source><year>2007</year><volume>26</volume><fpage>800</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">17335054</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tissot</surname><given-names>W</given-names></name><name><surname>Amundsen</surname><given-names>CL</given-names></name><name><surname>Diokno</surname><given-names>AC</given-names></name><name><surname>Webster</surname><given-names>GD</given-names></name><name><surname>Coats</surname><given-names>AC</given-names></name></person-group><article-title>Bladder diary measurements in asymptomatic males: frequency, volume per void, and 24&#x02013;hr volume</article-title><source>Neurourol Urodyn.</source><year>2008</year><volume>27</volume><fpage>198</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">17638309</pub-id></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amundsen</surname><given-names>CL</given-names></name><name><surname>Parsons</surname><given-names>M</given-names></name><name><surname>Cardozo</surname><given-names>L</given-names></name><name><surname>Vella</surname><given-names>M</given-names></name><name><surname>Webster</surname><given-names>GD</given-names></name><name><surname>Coats</surname><given-names>AC</given-names></name></person-group><article-title>Bladder diary volume per void measurements in detrusor overactivity</article-title><source>J Urol.</source><year>2006</year><volume>176</volume><fpage>2530</fpage><lpage>2534</lpage><pub-id pub-id-type="pmid">17085150</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>EP</given-names></name><name><surname>Malone</surname><given-names>DC</given-names></name><name><surname>Bui</surname><given-names>CN</given-names></name></person-group><article-title>Cost&#x02013;effectiveness analysis of anti&#x02013;muscarinic agents for the treatment of overactive bladder</article-title><source>J Med Econ.</source><year>2012</year><volume>15</volume><issue>Suppl 1</issue><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">22998646</pub-id></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geoffrion</surname><given-names>R</given-names></name></person-group><article-title>Treatments for overactive bladder: focus on pharmacotherapy</article-title><source>J Obstet Gynaecol Can.</source><year>2012</year><volume>34</volume><fpage>1092</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">23231848</pub-id></element-citation></ref><ref id="CIT0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chancellor</surname><given-names>MB</given-names></name><name><surname>Anderson</surname><given-names>RU</given-names></name><name><surname>Boone</surname><given-names>TB</given-names></name></person-group><article-title>Pharmacotherapy for neurogenic detrusor overactivity</article-title><source>Am J Phys Med.</source><year>2006</year><volume>85</volume><fpage>536</fpage><lpage>545</lpage></element-citation></ref><ref id="CIT0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horstmann</surname><given-names>M</given-names></name><name><surname>Schaefer</surname><given-names>T</given-names></name><name><surname>Aguilar</surname><given-names>Y</given-names></name><name><surname>Stenzl</surname><given-names>A</given-names></name><name><surname>Sievert</surname><given-names>KD</given-names></name></person-group><article-title>Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage</article-title><source>Neurourol Urodyn.</source><year>2006</year><volume>25</volume><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">16847942</pub-id></element-citation></ref><ref id="CIT0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amend</surname><given-names>B</given-names></name><name><surname>Hennenlotter</surname><given-names>J</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>T</given-names></name><name><surname>Horstmann</surname><given-names>M</given-names></name><name><surname>Stenzl</surname><given-names>A</given-names></name><name><surname>Sievert</surname><given-names>K.&#x02013;D</given-names></name></person-group><article-title>Effective Treatment of Neurogenic Detrusor Dysfunction by Combined High&#x02013;Dosed Antimuscarinics without Increased Side&#x02013;Effects</article-title><source>Eur Urol.</source><year>2008</year><volume>53</volume><fpage>1021</fpage><lpage>1028</lpage><pub-id pub-id-type="pmid">18243516</pub-id></element-citation></ref><ref id="CIT0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>KE</given-names></name></person-group><article-title>Muscarinic acetylcholine receptors in the urinary tract</article-title><source>Handb Exp Pharmacol.</source><year>2011</year><volume>202</volume><fpage>319</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">21290234</pub-id></element-citation></ref><ref id="CIT0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Igawa</surname><given-names>Y</given-names></name><name><surname>Aizawa</surname><given-names>N</given-names></name><name><surname>Homma</surname><given-names>Y</given-names></name></person-group><article-title>Beta3&#x02013;adrenoceptor agonists: possible role in the treatment of overactive bladder</article-title><source>Korean J Urol.</source><year>2010</year><volume>51</volume><fpage>811</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">21221199</pub-id></element-citation></ref><ref id="CIT0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>AJ</given-names></name></person-group><article-title>Afferent mechanism in the urinary tract</article-title><source>Handb Exp Pharmacol.</source><year>2011</year><volume>202</volume><fpage>171</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">21290227</pub-id></element-citation></ref><ref id="CIT0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapple</surname><given-names>CR</given-names></name><name><surname>Khullar</surname><given-names>V</given-names></name><name><surname>Gabriel</surname><given-names>Z</given-names></name><name><surname>Muston</surname><given-names>D</given-names></name><name><surname>Bitoun</surname><given-names>CE</given-names></name><name><surname>Weinstein</surname><given-names>D</given-names></name></person-group><article-title>The effects of antimuscarinic treatments in overactive bladder, an update of a systematic review and metaanalysis</article-title><source>Eur Urol.</source><year>2008</year><volume>54</volume><fpage>543</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">18599186</pub-id></element-citation></ref><ref id="CIT0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>KE</given-names></name></person-group><article-title>Antimuscarinics for treatment of overactive bladder</article-title><source>Lancet Neurology</source><year>2004</year><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">14693111</pub-id></element-citation></ref><ref id="CIT0033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korstanje</surname><given-names>C</given-names></name><name><surname>Krauwinkel</surname><given-names>W</given-names></name></person-group><article-title>Specific pharmacokinetic aspects of the urinary tract</article-title><source>Handb Exp Pharmacol.</source><year>2011</year><volume>202</volume><fpage>267</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">21290231</pub-id></element-citation></ref></ref-list></back></article>